Abstract Regulatory T cells (Tregs) are essential for maintaining immune homeostasis and preventing autoimmune diseases, but are also a major cellular constituent of the tumor microenvironment (TME) that facilitates cancer progression. Identifying differences in Treg subtypes to specifically disrupt the activities of tumor-promoting Tregs, without affecting Tregs that maintain immune homeostasis remain a challenge.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ephraim A. Ansa-Addo
The chromatin-organizer Satb1 modulates regulatory T cell activity within the tumor microenvironment
Autocrine transforming growth factor β1 in regulatory T cell biology-gone but not missed
Despite the pivotal and well-defined roles of transforming growth factor beta 1 (TGF-β1) in the generation of peripheral regulatory T (Treg) cells, the contribution of Treg-cell-derived TGF-β1 to their suppressive function and ultimately to peripheral tolerance has been largely obscure. Recently, Turner et al. sought to examine the physiological roles of Treg-cell-derived TGF-β1 by mating mice with loxP-flanked Tgfb1exon6 allele ( Azhar et al., 2009 Azhar M. Yin M. Bommireddy R. Duffy J.J. Yang J.
RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity
Abstract Distinct lineages of T cells can act in response to various environmental cues to either drive or restrict immune-mediated pathology. Here, we identify the RNA binding protein, poly(C)-binding protein 1 (PCBP1) as an intracellular immune checkpoint that is up-regulated in activated T cells to prevent conversion of effector T (Teff) cells into regulatory T (Treg) cells, by restricting the expression of Teff cell–intrinsic Treg commitment programs.
Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade
Brian P. Riesenberg, Ephraim A. Ansa-Addo, Jennifer Gutierrez, Cynthia D. Timmers, Bei Liu and Zihai Li J Immunol September 1, 2019, 203 (5) 1105-1110; DOI: https://doi.org/10.4049/jimmunol.1900594 Key Points Platelets alter frequency, phenotype, and function of tumor-infiltrating lymphocytes. Inhibition of platelet activation improves CD8+ T cell–dependent tumor control. Pretreatment with antiplatelet therapy enhances responsiveness to PD-1 blockade.
Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade
Brian P. Riesenberg, Ephraim A. Ansa-Addo, Jennifer Gutierrez, Cynthia D. Timmers, Bei Liu and Zihai Li J Immunol July 29, 2019, ji1900594; DOI: https://doi.org/10.4049/jimmunol.1900594 Key Points Platelets alter frequency, phenotype, and function of tumor-infiltrating lymphocytes. Inhibition of platelet activation improves CD8+ T cell–dependent tumor control. Pretreatment with antiplatelet therapy enhances responsiveness to PD-1 blockade.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ephraim A.
Contact Ephraim A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack